摘要
Abstract
Objective:To analyze the therapeutic efficacy of Recombinant Human Erythropoietin combined with Oron in the treatment of anemia in premature children.Method:According to different treatment methods 68 cases of premature infants were randomly selected from January 2014 to January 2015,and were divided into study group and control group,34 cases in each group.The control group was given routine prevention of anemia treatment,the study group was given recombinant human erythropoietin combined with iron therapy,the effects of two groups were compared.Result:PLT,WBC of the study group had no significant differences compared with the control group (P>0.05).RBC,HCT and Hb of the study group compared with the control group,there were statistical difference(P<0.05).The incidence rate of adverse reaction of the study group was 17.6%,the control group was 50.0%,there was statistical difference(P<0.05).Conclusion:In clinical prevention and treatment of anemia of prematurity and application of recombinant human erythropoietin combined iron therapy can reduce the incidence of anemia of prematurity,improve the anemia of prematurity and the incidence of adverse reactions,has high safety,prevention and treatment of anemia of prematurity hair play a positive role.关键词
铁剂/早产儿/贫血/重组人类促红细胞生成素Key words
Iron/Premature infants/Anemia/Recombinant human erythropoietin
